Roche Holding AG (RHHBY) on Decifer Markets
Decifer Markets ranks RHHBY number 264 of 276 tracked names on durable business quality.
Why it ranks here
- It keeps about 21 cents of every sales dollar as cash, safer than 85 in 100 companies we measure.
- It earns about 20% a year on the money put into the business, better than 85 in 100 companies we measure.
- Its share price rose about 27% over the past year, leaving out the latest month. Stronger than 61 in 100 companies we measure.
- We could not measure 4 of the seven scores for this company: price, profit on assets, share count and careful growth. Each counts as 50, the middle, until we can.
The current read
The evidence on RHHBY lines up on the supportive side: a live market force supports this name through its theme connection. The independent signals we track are telling the same story.
Themes
- Genomic Medicine & Precision Diagnostics: The collapsing cost of DNA/RNA sequencing and validation of genomic classifiers is moving clinical practice toward routine molecular diagnostics and companion testing.
Read the full RHHBY research brief · See all quality rankings
Intelligence data powered by Decifer. Not financial advice. For informational purposes only.